Form 4: Caris Life Sciences Executive Brian Brille Boosts Stake with Significant Stock Acquisitions

Brian J. Brille, Vice Chairman and Executive Vice President of Caris Life Sciences, reported acquiring 162,428 shares of common stock through a restricted stock unit award and a direct purchase.

Summary

• Brian J. Brille, serving as Director, Vice Chairman, and Executive Vice President of Caris Life Sciences, Inc. (CAI), reported changes in his beneficial ownership of the company's common stock.
• On June 18, 2025, Brille acquired 132,428 shares of common stock through an award of restricted stock units (RSUs) at a price of $0.00 per share, which are set to vest in accordance with the applicable grant agreement.
• On June 20, 2025, Brille further increased his direct holdings by purchasing 30,000 shares of common stock at a price of $21.00 per share.
• Following these transactions, Brille directly beneficially owns 162,428 shares of common stock.
• Additionally, Brille indirectly beneficially owns 500,000 shares of common stock held by trusts, though he disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Sentiment

Score: 8

Explanation: The significant acquisition of shares by a high-ranking executive and director, including a direct purchase, indicates strong insider confidence and is generally viewed positively by the market.

Positives

• The acquisition of 162,428 shares by a key executive and director, Brian J. Brille, signals strong insider confidence in the company's future prospects.
• The direct purchase of 30,000 shares at $21.00 per share represents a significant personal investment at market price, indicating a belief in the current valuation and future appreciation.
• The award of 132,428 restricted stock units aligns management's long-term interests directly with shareholder value through their vesting schedule.

Future Outlook

This Form 4 filing is a transactional report and does not contain specific forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
• The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Industry Context

Insider buying, particularly by a high-ranking executive and director in the life sciences sector, can be interpreted as a positive signal, suggesting confidence in the company's strategic direction, pipeline, or market position within the broader industry.

Related Party Transactions

• The indirect beneficial ownership of 500,000 shares through trusts is disclosed, with the reporting person disclaiming beneficial ownership except for pecuniary interest.
• The award of 132,428 restricted stock units is a compensation-related transaction between the company and the executive.

Stakeholder Impact

• Shareholders: The insider buying could be perceived as a strong vote of confidence from management, potentially leading to increased investor interest and positive share price movement.
• Management/Employees: The restricted stock unit award aligns the executive's financial interests with the long-term performance and success of the company.

Key Dates

Recommendation

Keywords

Caris Life Sciences, CAI, SEC Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, Brian J Brille, Executive Stock Purchase, Director Stock Ownership, Beneficial Ownership